Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Ferring Pharmaceuticals

Drug Profile

Somatropin - Ferring Pharmaceuticals

Alternative Names: Tev-Tropin; TevTropin; ZOMACTON; Zomacton

Latest Information Update: 06 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Savient Pharmaceuticals
  • Developer Elvetium; Ferring Pharmaceuticals; Teva Pharmaceuticals USA
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Discontinued Cachexia

Most Recent Events

  • 06 Feb 2018 FDA approves somatropin for Somatotrophin deficiency (In adults) in USA (ADNM)
  • 31 Jan 2018 Registered for Somatotropin deficiency (In adults) in USA (SC; 5mg, 10mg)
  • 10 Oct 2017 Ferring Pharmaceuticals entered into an asset purchase agreement to acquire worldwide rights to somatotropin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top